Cytiva acquires Vanrx Pharmasystems, Canadian aseptic filling innovator | Information


– Cytiva will now offer Idea to Injection solutions to customers and the market

– The expansion of the portfolio supports global trends towards smaller manufacturing and the emergence of personalized therapies

– First takeover by the company since Cytiva in April 2020

AMERSHAM, Great Britain, February 1, 2021 / PRNewswire / – Cytiva has acquired Vanrx Pharmasystems, a Canadian company that manufactures robotic aseptic filling machines for filling vials, syringes and cartridges with reduced risk and increased speed for patients.

This is Cytiva’s first acquisition. Emmanuel Ligner, President and CEO of Cytiva, says, “Since I’ve been in a Danaher company April 2020We have already started to innovate and reinvest in business for the benefit of our customers and their patients. We are very pleased to welcome the Vanrx employees into our family and look forward to working together to deliver meaningful solutions for organic producers. “

The Vanrx portfolio complements Cytiva’s production capacity solutions. While great advances to date have focused on drug substances, this innovation is focused on drugs, which is a critical final step before distribution to patients. Global trends towards smaller batches and personalized therapies are changing growth $ 300 billion Biologics market[1]and the entire bioprocess workflow must include aseptic filling solutions.

Olivier Loeillot, Vice President and Head of BioProcess, Cytiva, said: “Cytiva will be the first biotechnology company to add Vanrx to our already strong portfolio. From drug development to drug substance to drug, we can.” Helping organic producers deliver their therapies to patients faster. Vanrx will enhance the Cytiva FlexFactory platforms and modular facilities of KUBio, and allow us to accelerate organic production from start to finish. “

Vanrx’s flagship products are the SA25 Aseptic Filling Workcell and the Microcell Vial Filler, which use robotics to automate aseptic filling in closed, glove-free isolators. These standardized, flexible systems provide a quick and safe route to fill capacity as the final step in the manufacture of clinical and commercial biopharmaceuticals. The company counts leading biopharmaceutical companies among its customers.

Vanrx was founded in 2007 by Chris Procyshyn and Ross Gold There are currently over 120 employees, all of whom have been offered jobs at Cytiva.

Chris ProcyshynVanrx, Co-Founder and CEO, says, “We developed Vanrx so that any business could create safe, affordable injectable therapies. Our own experience has shown the need for new technologies to support next generation therapies and personalized medicine.

“Cytiva is a perfect home for what we have built. With its reach, we can help our current and future customers change the lives of even more patients around the world.”

Manufacturer: Click here for the B-roll of aseptic filling solutions.

For more information on Cytiva Business Solutions, click here.


About Cytiva

Cytiva is a global leader in the life sciences with more than 7,000 employees in 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner for customers of all sizes and scopes, Cytiva provides speed, efficiency and capacity for research and manufacturing operations, enabling the development, manufacture and delivery of transformative medicines to patients.


1 BioPlan and Associates 17th Annual Biopharmaceutical Manufacturing Capacity and Manufacturing (April 2020)

To download multimedia, view the original content at: